JAZZ - In Jazz acquisition of GW Pharma Epidiolex is tip of cannabinoid iceberg

With its $7.2B acquisition of GW Pharmaceuticals (GWPH), Jazz Pharmaceuticals (JAZZ) has acquired more than just GW's key cannabinoid product, Epidiolex, for seizures in certain conditions.Based on preliminary figures, sales of Epidiolex were around $510M in 2020.The most advanced cannabinoid candidate in GW's pipeline for the U.S. is Nabiximols in phase 3 for multiple sclerosis spasticity and spinal cord injury spasticity.Nabiximols, also known as Sativex, is a cannabis extract spray that contains the cannabinoids THC and CBD, and is also in phase 2 for PTSD.Sativex is approved in the U.K., Switzerland, Norway, Turkey, Israel, Canada, Australia, New Zealand, Brazil, Colombia, and Chile.In phase 2, GW is also investigating other cannabinoids for schizophrenia and autism spectrum disorders.In phase 1, the company is examining cannabinoids for neonatal hypoxic-ischemic encephalopathy and neuropsychiatry targets.GW shares are up 46.3% to $213.99 and Jazz shares are down 2.1% to $153.99 in afternoon trading

For further details see:

In Jazz acquisition of GW Pharma, Epidiolex is tip of cannabinoid iceberg